Literature DB >> 7082083

Mediastinal metastases in bronchogenic carcinoma: influence of postoperative irradiation, cell type, and location.

M M Kirsh, H Sloan.   

Abstract

A 17-year experience with 136 patients with bronchogenic carcinoma and mediastinal metastases is reported. Six died postoperatively. Postoperative mediastinal irradiation was given to 110 patients surviving curative resection who had evidence of tumor spreading to the mediastinal lymph nodes. The remaining 20 patients did not receive radiation therapy. Of the 136 patients, 29 (21.3%) lived 5 years free from disease and 9 survived 10 or more years. Of the 110 patients who survived operation and underwent irradiation, 29 (26.4%) survived 5 years. None of the 20 patients not receiving radiation therapy lived 5 years. Of the patients who underwent irradiation, 18 of the 50 patients with squamous cell carcinoma survived 5 years, while only 7 of 55 with adenocarcinoma survived 5 years. We do not believe that the discovery of mediastinal lymph node involvement in bronchogenic carcinoma is a contraindication to pulmonary resection. As in our previous reports, histological cell type has proved to be an important indicator of absolute survival. Patients with squamous cell carcinoma had an absolute-5-year survival of 33.9%, while the patients with adenocarcinoma had an absolute survival of 12.3%. The level of lymph node metastasis has an influence on prognosis as well. Patients with subcarinal lymph node metastases had a lower survival than patients with superior mediastinal involvement.

Entities:  

Mesh:

Year:  1982        PMID: 7082083     DOI: 10.1016/s0003-4975(10)60786-2

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  11 in total

1.  Mediastinal lymphatic drainage from pulmonary lobe based on CT observations of histoplasmosis: implications for minimal N2 disease of non-small-cell lung cancer.

Authors:  Koji Takahashi; William Stanford; Edwin Van Beek; Brad Thompson; Brian Mullan; Yutaka Sato
Journal:  Radiat Med       Date:  2007-10-26

Review 2.  Role of postoperative radiotherapy in resected non-small cell lung cancer: a reassessment based on new data.

Authors:  Cécile Le Péchoux
Journal:  Oncologist       Date:  2011-03-04

3.  Survival after resection for primary lung cancer: a population based study of 3211 resected patients.

Authors:  T-E Strand; H Rostad; B Møller; J Norstein
Journal:  Thorax       Date:  2006-04-06       Impact factor: 9.139

4.  Subcarinal node is the significant node that affects survival in resected small cell lung cancer.

Authors:  Masaki Miyamoto; Toshiaki Morikawa; Kichizo Kaga; Setsuyuki Ohtake; Yasushi Cho; Satoshi Hirano; Satoshi Kondo
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

5.  A randomized comparison of the effects of adjuvant therapy on resected stages II and III non-small cell carcinoma of the lung. The Lung Cancel Study Group.

Authors:  E C Holmes; L D Hill; M Gail
Journal:  Ann Surg       Date:  1985-09       Impact factor: 12.969

Review 6.  Extended resection for higher-stage non-small-cell lung cancer.

Authors:  J D Luketich; D E van Raemdonck; R J Ginsberg
Journal:  World J Surg       Date:  1993 Nov-Dec       Impact factor: 3.352

Review 7.  Lung cancer--current concepts and controversies.

Authors:  S B Pett; J A Wernly; B F Akl
Journal:  West J Med       Date:  1986-07

Review 8.  Resection of stage III non-small cell lung cancer following induction therapy.

Authors:  V W Rusch
Journal:  World J Surg       Date:  1995 Nov-Dec       Impact factor: 3.352

9.  Non-small-cell lung cancer: detection of mediastinal lymph node metastases by endoscopic ultrasound and CT.

Authors:  P Potepan; E Meroni; I Spagnoli; M Milella; G M Danesini; A Laffranchi; E Civelli; M Alloisio; L Mariani; P Spinelli; A Guzzon
Journal:  Eur Radiol       Date:  1996       Impact factor: 5.315

Review 10.  Non-small-cell lung carcinoma. Current and future therapeutic management.

Authors:  K T Bastin; R Curley
Journal:  Drugs       Date:  1995-03       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.